SARS-CoV-2-IN-34

SARS-CoV-2-IN-34 (0.1-100 μM; 30 min) inhibits infection by PsV of SARS variants on Huh-7 and Caco-2 cells with IC₅₀s values ranging from 0.54 to 10.23 μM and inhibits infection of pseudotyped SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, and bat SARSr-CoV WIV1 with IC₅₀s ranging from 1.30 to 12.02 μM^[1].
SARS-CoV-2-IN-34 (0.1-100 μM; 30 min) inhibits the replication of authentic SARS-CoV 2 on Caco-2 cell line with an IC₅₀ value of 8.14 μM and inhibits authentic HCoV-OC43 and HCoV-229E infection in RD cells and Huh-7 cells with IC₅₀s of 6.25 and 9.46 μM, respectively^[1].
SARS-CoV-2-IN-34 (0.1-100 μM; 2-4 h) potently inhibits cell-cell fusion mediated by S protein of SARS-CoV-2, SARS-CoV, MERS CoV, HCoV-229E and HCoV-NL63 with IC₅₀s ranging from 1.47 to 5.44 μM^[1].
SARS-CoV-2-IN-34 (50 μM; 1 h) inhibits SARS-CoV-2 infection at the early stage of viral entry^[1].
SARS-CoV-2-IN-34 (0-2 μM) shows binding effects to S1, RBD and HR with K_d value of 67, 61 and 277 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.